DelveInsights launched a new report on Intrahepatic Cholangiocarcinoma (ICCA) Market Insights, Epidemiology and Market Forecast 2030.
DelveInsight’s ‘Intrahepatic Cholangiocarcinoma (ICCA) Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the ICCA, historical and forecasted epidemiology as well as the ICCA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan
Intrahepatic cholangiocarcinoma (ICCA), a primary malignant neoplasm of the liver secondary to hepatocellular carcinoma, arises from the intrahepatic biliary epithelium (lining epithelia and peribiliary glands) and shows a variable cholangiocytic differentiation. The malignant tumor may arise from any portion of the bile duct epithelium, i.e., anywhere from the terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural).
Intrahepatic Cholangiocarcinoma (ICCA) Epidemiology Insights:
Request for sample pages of the report: https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-market
Intrahepatic Cholangiocarcinoma (ICCA) Emerging Therapies:
1. Pemazyre (Pemigatinib): Incyte Corporation
2. Rozlytrek (Entrectinib): Roche
3. Melphalan/HDS: Delcath Systems
4. Derazantinib: Basilea Pharmaceutica
Intrahepatic Cholangiocarcinoma (ICCA) Market Outlook
Intrahepatic cholangiocarcinoma (ICCA) is the type of CCA that forms in the bile ducts inside the liver. The commonly available modalities for the treatment of ICCA include surgery and radiation therapies for curative intent and systemic therapies, including chemotherapy and chemoradiotherapy, for the surgery of ineligible patients.
Surgical resection is the mainstay for the treatment of ICCA. The main goal of the surgery is the hepatic resection with negative margins. Since this type of cancer occurs in the bile ducts inside the liver, surgery may include removing the section or wedge of the liver, and its extent depends on tumor size and location.
Locoregional therapies such as RFA, TACE, DEB-TACE or TACE drug-eluting microspheres, and TARE with yttrium-90 microspheres have shown to be effective in a retrospective analysis of patients with ICCA. Besides these, radiation therapy is also a locoregional treatment option for unresectable ICCA. Fewer patients with ICCA are also given ablation. Although all guidelines recommend radiofrequency ablation (RFA) as a standard treatment for patients with small, early-stage HCC not suitable for surgical therapies, in some cases, patients with ICCA are also treated with RFA.
Click here and get access to free sample pages of the report.
Intrahepatic Cholangiocarcinoma (ICCA) Market Insights
Table of contents:
1 Key Insight2 Executive Summary of Intrahepatic Cholangiocarcinoma (ICCA)3 Intrahepatic Cholangiocarcinoma (ICCA) Market Overview at a Glance4 Disease Background and Overview: Intrahepatic Cholangiocarcinoma (ICCA)5 Case Reports6 Intrahepatic Cholangiocarcinoma (ICCA) Epidemiology and Patient Population7 United States Epidemiology8 EU5 Epidemiology9 Japan Epidemiology10 Current Intrahepatic Cholangiocarcinoma (ICCA) Treatment and Medical Practices11 Unmet needs12 Intrahepatic Cholangiocarcinoma (ICCA) Marketed Drugs13 Intrahepatic Cholangiocarcinoma (ICCA) Emerging Drugs14 Intrahepatic Cholangiocarcinoma (ICCA) 7MM Market Analysis15 United States16 EU-5 countries: Market Outlook17 Japan Market Outlook18 Intrahepatic Cholangiocarcinoma (ICCA) Market Drivers19 Intrahepatic Cholangiocarcinoma (ICCA) Market Barriers20 SWOT Analysis21 Reimbursement and market access22 Appendix23 DelveInsight Capabilities24 Disclaimer25 About DelveInsight
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/